Evolution Biotechnologies announces positive outcome of international patent search and examination on key patent filing - Evolution Biotechnologies
post-template-default,single,single-post,postid-7934,single-format-standard,ajax_fade,page_not_loaded,,qode-title-hidden,qode-theme-ver-16.4,qode-theme-bridge,wpb-js-composer js-comp-ver-5.4.7,vc_responsive

Evolution Biotechnologies announces positive outcome of international patent search and examination on key patent filing

Bedford, UK, November 14th 2017

­Evolution Biotechnologies (www.evolutionbiotech.com), the UK and US-based company extending the use of biological control into medically important areas, today announced the highly positive outcome of the international (PCT) stage search and examination of its key patent filing PCT/GB2016/052455, “Acaricides”. The examination, conducted by the European Patent Office (EPO), confirmed the broad claim to a method of treating or preventing a house dust mite infestation using an acaricidal infectious agent as both novel and inventive. This is a key step towards obtaining broad protection for the work of the company in controlling house dust mites, a major cause of asthma and other allergic conditions in both humans and companion animals.

Dr. David Harper, Chief Executive Officer of Evolution, said “This is an important step for the company, validating our work to date and taking us a lot closer to developing products to benefit millions of asthmatics worldwide. I look forward to progressing this application through the national stages and on to award, based on this very promising result.”

About Evolution Biotechnologies

Evolution Biotechnologies (UK company 09473027) has been established to extend the application of biological control from its agricultural roots into areas of biomedical importance. The company’s initial targets have both significant unmet need and high market potential. The first stage of Evolution’s work is based on the outcomes of a successful feasibility study on biological control of the house dust mite. The company is also workong to develop further biological controls, including phage therapy for the antibiotic resistant superbug Pseudomonas aeruginosa. This will initially target disease in companion animals as a basis for the later development of human therapeutics.

About biological control

Biological control is highly specific in nature, and is perceived as environmentally friendly. The US Environmental Protection Agency (EPA) has stated that “Since biopesticides tend to pose fewer risks than conventional pesticides, EPA generally requires much less data to register a biopesticide”. Biological control methodologies have been extensively used in the agricultural and food safety sectors and provide a “green” alternative to existing chemical approaches, especially where there are concerns over toxicity or resistance. Despite the validated route through the regulatory process and onto the market, application in the domestic and medical settings has received only limited attention to date.

Forward-looking statements

This document contains certain forward-looking statements – i.e., statements that are not historical facts, including statements about our beliefs and expectations. These statements are based on plans, estimates and projections at the time we make the statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement.

Media contacts;

Email:      enquiries@evolutionbiotech.com

Website:   www.evolutionbiotech.com

No Comments

Sorry, the comment form is closed at this time.